tradingkey.logo

Cryo-Cell International Inc

CCEL
View Detailed Chart

4.850USD

+0.350+7.78%
Close 09/19, 16:00ETQuotes delayed by 15 min
39.11MMarket Cap
LossP/E TTM

Cryo-Cell International Inc

4.850

+0.350+7.78%
Intraday
1m
30m
1h
D
W
M
D

Today

+7.78%

5 Days

+7.30%

1 Month

+10.98%

6 Months

-22.03%

Year to Date

-34.55%

1 Year

-21.39%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
34 / 72
Overall Ranking
189 / 4720
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
8.500
Target Price
+88.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Growing
The company is in a growing phase, with the latest annual income totaling USD 31.99M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 402.10K.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -250.26, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.28M shares, decreasing 0.16% quarter-over-quarter.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Ticker SymbolCCEL
CompanyCryo-Cell International Inc
CEOMr. Mark L. Portnoy
Websitehttps://www.cryo-cell.com/
KeyAI